Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plavix in high-risk patients at risk of atherothrombotic events (CHARISMA)
NCT00050817Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2002
- Countries
- 32
- Sponsor
- Sanofi
- Modality
- Small Molecules
- Drugs
- clopidogrel
- Conditions
- atherothrombosis
01
Overview
Phase 3, randomised, double-blind trial in atherothrombosis comparing Clopidogrel + Aspirin with Placebo + Aspirin (2 arms). Primary endpoint: Major Adverse Cardiovascular Events at 3.5 years. Started Oct 2002; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Clopidogrel + Aspirin
Active clopidogrel 75mg daily on top of background low-dose aspirin.
Placebo + Aspirin
Matching placebo daily on top of background low-dose aspirin.
03
Endpoints
Primary
Major Adverse Cardiovascular Events
Secondary
Severe bleeding
Composite of CV death, MI, stroke, or hospitalization for ischemic events
Beyond the preview
Go deeper on NCT00050817.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050817.